関連文献

Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.

Diabet Med. 29(8): e184-190, 2012.PubMed

Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.

Hypertens Res. 35(11): 1058-1062, 2012.PubMed

Potential Benefit of Statin Therapy for Dyslipidemia with Chronic Kidney Disease: Fluvastatin Renal Evaluation Trial (FRET).

Internal Medicine. 50(12): 1273-1278, 2011.PubMed

Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.

Hypertens Res . 34: 935-941, 2011.PubMed

Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.

Am J Med Sci. 339(2): 157-163, 2010.PubMed

Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.

Kidney Blood Press Res. 33(3): 213-220, 2010.PubMed

Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.

Eur J Clin Invest. 40(9): 790-796, 2010.PubMed

Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury.

Am J Pathol. 174(4): 1203-1211, 2009.PubMed

Tubular and glomerular injury in diabetes and the impact of ACE inhibition.

Diabetes Care. 32(9): 1684-1688, 2009.PubMed

Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury.

Kidney Int. 73(12): 1374-1384, 2008.PubMed